Clinical trial
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In…
NCT00174278 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00174278 |
|---|---|
| Title | Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary |
| Official title | Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Hormone Deficiency, Growth Retardation |
| Intervention type | Drug |
| Interventions | Somatropin |
| Enrollment | 14 |
| Start date | Feb 1, 1997 |
| Completion | Oct 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Aug 5, 2008 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: